Clinical trials
Breast Neoplasms clinical trials
Below are recruiting breast neoplasms clinical trials, each written for real people, not researchers. We’re tracking 233 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06365788RecruitingPhase 2
Bicalutamide and Abemaciclib for AR-positive Triple-negative Breast Cancer
This trial tests a combination of two oral drugs—bicalutamide and abemaciclib—for people with a specific type of advanced triple-negative breast cancer that grows in response to androgen hormones (AR-positive). The goal is to see if this treatment can shrink tumors or slow disease progression.
AntwerpAges 18 years+ - NCT07698366Recruiting
Ultrasound screening for breast cancer in older women
This study tests if ultrasound screening can help find breast cancer early in women aged 65–80 who live in the community. Participants will have an ultrasound exam to check for signs of breast cancer.
Kunshan, JiangsuAges 65–80 - NCT05334069Recruiting
Blood test study for early cancer detection in patients
This study collects blood from people with cancer and people without cancer (or with possible cancer) to test whether new blood tests can detect cancer earlier. Your blood samples help researchers evaluate how well these tests work.
Anchorage, AlaskaAges 40–75 - NCT05978648RecruitingPhase 2
Trilaciclib for early-stage HR-negative breast cancer after surgery
This trial tests if adding trilaciclib to standard chemotherapy after surgery can help people with hormone receptor-negative breast cancer. It aims to reduce side effects and improve treatment outcomes.
Guangzhou, GangdongAges 18 years+ - NCT06318507Recruiting
Gut Bacteria and Immunotherapy for Triple-Negative Breast Cancer
This study looks at how bacteria in your gut might affect the way your body responds to immunotherapy for triple-negative breast cancer. It focuses on women who are overweight or obese and are about to start treatment with pembrolizumab before surgery.
Baton Rouge, LouisianaAges 18 years+ - NCT07060807RecruitingPhase 3
Patritumab deruxtecan for advanced breast cancer
This study tests an investigational drug called patritumab deruxtecan for people with a certain type of advanced breast cancer that is hormone receptor-positive and HER2-negative. The drug targets a protein called HER3, which is common on these cancer cells, and may slow or shrink the cancer when previous treatments have stopped working.
Daphne, AlabamaAges 18 years+ - NCT05071105Recruiting
Short-course radiation for early breast cancer in older women
This study looks at a brief type of radiation called SBRT given soon after starting hormone therapy for certain early breast cancers in women age 75 and older. It may help treat the cancer locally while aiming to be easier to receive than longer radiation schedules.
Rome, RomeAges 75 years+ - NCT06312176RecruitingPhase 3
Study of new drugs for HR+/HER2- advanced breast cancer
This trial tests two new drugs (sacituzumab tirumotecan and pembrolizumab) against standard treatments for a type of advanced breast cancer that is hormone receptor positive and HER2 negative. It's for people whose cancer has worsened despite hormone therapy with a CDK4/6 inhibitor.
Chandler, ArizonaAges 18 years+ - NCT07042581RecruitingPhase 4
Revaree Plus for vaginal dryness in breast cancer survivors
This trial tests a vaginal insert called Revaree Plus to see if it helps breast cancer survivors who have vaginal dryness or pain from hormone therapy. It may be a good option if you are on an aromatase inhibitor or tamoxifen and have discomfort.
Basking Ridge, New JerseyAges 18 years+ - NCT07222215RecruitingPhase 2
Capacitabine with or without elacestrant for ER+ breast cancer
This trial tests if adding a new oral targeted therapy (elacestrant) to standard chemotherapy (capecitabine) works better than chemotherapy alone for people with a specific type of advanced breast cancer that is hormone-sensitive (ER-positive) and has stopped responding to hormone therapy.
Boston, MassachusettsAges 18 years+ - NCT05427071Recruiting
Tracking a breast cancer marker to guide lymph node surgery
This study tests a special “marker” technique to help surgeons find affected lymph nodes in the armpit after chemotherapy. It may support more targeted surgery and help avoid unnecessary removal of healthy lymph nodes.
Hong KongAges 18 years+ - NCT06875414Recruiting
Breast cancer and couple resilience study
This study looks at how couples handle a breast cancer diagnosis and treatment together. Researchers want to understand how the relationship affects coping and well-being.
Roma, RomeAges 18 years+ - NCT07263347Recruiting
DIEP flap breast reconstruction: markers and outcomes
This study looks at how certain body markers change during and after DIEP flap breast reconstruction (rebuilding the breast with your own belly tissue) following mastectomy for breast cancer. It aims to improve outcomes and care for women undergoing this surgery.
Wuhan, HubeiAges 18–70 - NCT06505577Recruiting
Comparing Tumor Size Before and After Breast Cancer Surgery
This study compares the size of a breast tumor measured before surgery (using imaging tests like mammogram or ultrasound) with the actual size found after the tumor is removed. It helps understand how accurate preoperative measurements are for patients having breast cancer surgery.
IncheonAges 19 years+ - NCT06443645Recruiting
Protecting the heart during breast cancer treatment
This trial tests whether a diabetes medicine (SGLT2 inhibitor) can prevent heart damage caused by a common chemotherapy drug (anthracycline) in people with early-stage breast cancer. If you are newly diagnosed and about to start chemotherapy or have surgery, this study may be for you.
StrasbourgAges 18 years+ - NCT06291896Recruiting
Testing microwave imaging for breast cancer screening
This study tests a new, safe microwave-based device (MammoWave) to screen for breast cancer. It compares the device's results with standard mammograms to see if it can find cancer early in women at average risk.
Genova, GenovaAges 45–74 - NCT07225114RecruitingPhase 2
Better ultrasound imaging with contrast before biopsy
This trial tests a new, detailed ultrasound technique that uses a contrast agent (called Definity) to get clearer images of a suspicious area before a biopsy. It may help doctors better see the blood flow in the lesion, which could improve diagnosis.
Chapel Hill, North CarolinaAges 18 years+ - NCT06586957RecruitingPhase 1
Study of NKT3964 for advanced solid tumors
This trial tests an experimental drug called NKT3964 for people with certain advanced cancers that have stopped responding to standard treatments. It aims to see if the drug can shrink tumors or slow their growth.
Little Rock, ArkansasAges 19 years+ - NCT06830720Recruiting
Kisqali with hormone therapy for early-stage breast cancer
This study looks at how well Kisqali (ribociclib) combined with hormone therapy works after surgery for people with early-stage HR+ HER2- breast cancer that has a high chance of coming back. It aims to gather real-world data on different treatment options.
Wiener Neustadt, Lower AustriaAges 18–100 - NCT07046923RecruitingPhase 1
A study of LY4175408 for advanced cancer
This trial tests a new targeted drug (LY4175408) for people with certain advanced solid tumors (lung, endometrial, or triple negative breast cancer) who have already tried standard treatments. The goal is to see if the drug is safe and effective.
Stanford, CaliforniaAges 18 years+ - NCT06841354RecruitingPhase 3
Sac-TMT alone or with pembrolizumab for advanced triple-negative breast cancer
This trial tests a new drug, Sac-TMT, given alone or with an immunotherapy drug (pembrolizumab) for people with advanced triple-negative breast cancer who have not yet received any treatment for advanced disease. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Mobile, AlabamaAges 18 years+ - NCT04075305Recruiting
Study measuring radiation treatment outcomes with an MR-Linac
This study follows what happens when radiation treatment is guided using an MR-Linac (a special machine that combines MRI imaging with radiation). It may help improve how radiation therapy is planned and assessed, especially for people who can safely have MRI scans.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT07763587Recruiting
Acupuncture for breast cancer patients with mood or sleep problems
This study looks at how acupuncture (including ear acupuncture) can help women with breast cancer who also have emotional issues like anxiety, depression, trouble sleeping, or fatigue. It aims to see if this treatment improves their quality of life.
TianjinAges 18–70 - NCT05973864RecruitingPhase 2
Capecitabine plus pembrolizumab after TNBC surgery and chemo
This Phase 2 trial studies whether adding capecitabine to pembrolizumab after surgery can lower the risk of cancer coming back in people with triple-negative breast cancer that didn’t fully respond to earlier treatment. It’s meant for patients whose tumor was removed but still showed remaining cancer after chemo-immunotherapy.
AmiensAges 18 years+
Hear when a new Breast Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for breast neoplasms?
- Yes. Clin2 currently lists 233 recruiting breast neoplasms studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a breast neoplasms trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a breast neoplasms trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.